Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novavax Inc (NVAX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 199,465
  • Shares Outstanding, K 382,850
  • Annual Sales, $ 31,180 K
  • Annual Income, $ -183,770 K
  • 60-Month Beta 2.08
  • Price/Sales 4.77
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.54
  • Most Recent Earnings -0.12 on 11/07/18
  • Next Earnings Date 05/08/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.13
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -0.14
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +7.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.49 +12.61%
on 03/11/19
2.17 -74.57%
on 02/27/19
-1.54 (-73.60%)
since 02/19/19
3-Month
0.49 +12.61%
on 03/11/19
2.44 -77.39%
on 01/31/19
-1.61 (-74.45%)
since 12/19/18
52-Week
0.49 +12.61%
on 03/11/19
2.58 -78.61%
on 12/13/18
-1.54 (-73.60%)
since 03/19/18

Most Recent Stories

More News
Novavax: 4Q Earnings Snapshot

GAITHERSBURG, Md. (AP) _ Novavax Inc. (NVAX) on Monday reported a loss of $49.3 million in its fourth quarter.

NVAX : 0.55 (+5.91%)
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018.

NVAX : 0.55 (+5.91%)
Novavax, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Novavax, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 18, 2019 at 4:30 PM Eastern Time....

NVAX : 0.55 (+5.91%)
Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019

Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter 2018 financial and operating results prior to U.S. financial markets opening on Monday, March 18, 2019.

NVAX : 0.55 (+5.91%)
Is a Beat in Store for Catabasis (CATB) This Earnings Season?

Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.

CARA : 19.52 (+2.41%)
CATB : 7.11 (-3.27%)
TLRY : 69.79 (-3.39%)
NVAX : 0.55 (+5.91%)
What's in the Cards for Novavax (NVAX) This Earnings Season?

Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.

BDSI : 4.94 (+0.61%)
TLRY : 69.79 (-3.39%)
NVAX : 0.55 (+5.91%)
SNY : 45.14 (+0.51%)
Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax(TM) for Prevention of RSV Disease in Infants via Maternal Immunization

- Trial did not meet primary objective of prevention of medically significant RSV LRTI

NVAX : 0.55 (+5.91%)
Global Vaccine Adjuvants Market Outlook (2017-2026)

According to Stratistics MRC, the Global Vaccine Adjuvants Market is accounted for $460.21 million in 2017 and is expected to reach $1,330.25 million by 2026 growing at a CAGR of 12.5% from 2017 to 2026....

NVS : 92.99 (-0.19%)
NVAX : 0.55 (+5.91%)
CSLLY : 68.5450 (-2.23%)
MKKGY : 22.6700 (+0.82%)
Novavax Inc Falls 4.00% on Heavy Volume: Watch For Potential Rebound

Novavax Inc (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $1.89 to a high of $1.98. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $1.94 on...

NVAX : 0.55 (+5.91%)
Research Report Identifies Novavax, Zillow Group, Broadridge Financial Solutions, Summit Midstream Partners, LP, Primoris Services, and RE/MAX with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Novavax, Inc. (NASDAQ:NVAX),...

BR : 102.97 (-0.35%)
PRIM : 22.24 (-2.67%)
RMAX : 38.15 (-2.20%)
SMLP : 9.85 (+1.23%)
Z : 37.60 (-0.58%)
NVAX : 0.55 (+5.91%)
ZG : 36.89 (-0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade NVAX with:

Business Summary

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as...

See More

Key Turning Points

2nd Resistance Point 0.61
1st Resistance Point 0.58
Last Price 0.55
1st Support Level 0.51
2nd Support Level 0.47

See More

52-Week High 2.58
Fibonacci 61.8% 1.78
Fibonacci 50% 1.53
Fibonacci 38.2% 1.29
Last Price 0.55
52-Week Low 0.49

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar